Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Clearside Biomedical price target raised to $15 from $9 at Roth Capital » 09:47
06/18/21
06/18
09:47
06/18/21
09:47
CLSD

Clearside Biomedical

$4.19 /

-0.42 (-9.11%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah raised the firm's price target on Clearside Biomedical to $15 from $9 and keeps a Buy rating on the shares after the company earlier this week reported data from Cohort 1 of its Phase 1/2a dose-escalation study of CLS-AX in pretreated wet age-related macular degeneration patients. Jallah says that while she expected clean safety given the low dose, increases in best corrected visual acuity beyond that achieved with Eylea were a surprise. With this "encouraging start," the analyst added CLS-AX to her model.

ShowHide Related Items >><<
CLSD Clearside Biomedical
$4.19 /

-0.42 (-9.11%)

CLSD Clearside Biomedical
$4.19 /

-0.42 (-9.11%)

06/17/21 Wedbush
Clearside Biomedical price target raised to $18 from $6 at Wedbush
06/15/21 Roth Capital
Clearside reported 'impressive' data in wet AMD, says Roth Capital
06/02/21 Roth Capital
Clearside success with Xipere can derisk pipeline, says Roth Capital
05/18/21 Roth Capital
Clearside Biomedical price target raised to $9 from $8 at Roth Capital
CLSD Clearside Biomedical
$4.19 /

-0.42 (-9.11%)

CLSD Clearside Biomedical
$4.19 /

-0.42 (-9.11%)

Over a week ago
Recommendations
Clearside Biomedical price target raised to $18 from $6 at Wedbush » 08:13
06/17/21
06/17
08:13
06/17/21
08:13
CLSD

Clearside Biomedical

$4.05 /

-0.09 (-2.17%)

Wedbush analyst Liana…

Wedbush analyst Liana Moussatos raised the firm's price target on Clearside Biomedical to $18 from $6 and keeps an Outperform rating on the shares after the company reported positive initial safety results from cohort 1 of the Phase 1/2a OASIS study of CLS-AX in wAMD. The analyst argues that Clearside BioMedical is leveraging its proprietary suprachoroidal space microinjection platform to improve the delivery of drugs to treat eye diseases.

ShowHide Related Items >><<
CLSD Clearside Biomedical
$4.05 /

-0.09 (-2.17%)

CLSD Clearside Biomedical
$4.05 /

-0.09 (-2.17%)

06/15/21 Roth Capital
Clearside reported 'impressive' data in wet AMD, says Roth Capital
06/02/21 Roth Capital
Clearside success with Xipere can derisk pipeline, says Roth Capital
05/18/21 Roth Capital
Clearside Biomedical price target raised to $9 from $8 at Roth Capital
03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
CLSD Clearside Biomedical
$4.05 /

-0.09 (-2.17%)

CLSD Clearside Biomedical
$4.05 /

-0.09 (-2.17%)

On The Fly
Wall Street in Fives - Must Read Lists at Midday » 12:06
06/15/21
06/15
12:06
06/15/21
12:06
BA

Boeing

$245.71 /

+0.64 (+0.26%)

, EADSY

Airbus

$34.01 /

-0.02 (-0.06%)

, NVAX

Novavax

$189.20 /

-19 (-9.13%)

, AZN

AstraZeneca

$58.62 /

-0.13 (-0.22%)

, CLSD

Clearside Biomedical

$3.84 /

+0.8 (+26.32%)

, DCRC

Decarbonization Plus Acquisition III

$10.72 /

-1.31 (-10.89%)

, WPC

W.P. Carey

$77.50 /

-0.14 (-0.18%)

, CR

Crane

$91.42 /

+0.61 (+0.67%)

, ACRS

Aclaris Therapeutics

$17.59 /

-0.14 (-0.79%)

, CDAY

Ceridian

$85.53 /

-3.65 (-4.09%)

, FAST

Fastenal

$51.70 /

-1.03 (-1.95%)

, AMZN

Amazon.com

$3,371.43 /

-11.19 (-0.33%)

, DKNG

DraftKings

$48.28 /

-2.34 (-4.62%)

, DISH

Dish

$39.69 /

-0.335 (-0.84%)

, MSFT

Microsoft

$259.24 /

-0.71 (-0.27%)

, NFLX

Netflix

$494.25 /

-5.35 (-1.07%)

, OCGN

Ocugen

$6.59 /

+0.44 (+7.15%)

, ELAN

Elanco

$35.23 /

+1.73 (+5.16%)

, FOA

Finance of America

$8.83 /

+1.53 (+20.96%)

, SAGE

Sage Therapeutics

$60.33 /

-12.55 (-17.22%)

, VRM

Vroom

$40.55 /

-4.58 (-10.15%)

, SAVE

Spirit Airlines

$33.83 /

-0.125 (-0.37%)

, QD

Qudian

$2.25 /

-0.19 (-7.79%)

, BCOR

Blucora

$18.37 /

+1.4 (+8.25%)

, HLIO

Helios Technologies

$72.61 /

+0.64 (+0.89%)

, BBCP

Concrete Pumping

$8.44 /

-0.1 (-1.17%)

Get caught up quickly on…

ShowHide Related Items >><<
WPC W.P. Carey
$77.50 /

-0.14 (-0.18%)

VRM Vroom
$40.55 /

-4.58 (-10.15%)

SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

SAGE Sage Therapeutics
$60.33 /

-12.55 (-17.22%)

QD Qudian
$2.25 /

-0.19 (-7.79%)

OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

NVAX Novavax
$189.20 /

-19 (-9.13%)

NFLX Netflix
$494.25 /

-5.35 (-1.07%)

MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

HLIO Helios Technologies
$72.61 /

+0.64 (+0.89%)

FOA Finance of America
$8.83 /

+1.53 (+20.96%)

FAST Fastenal
$51.70 /

-1.03 (-1.95%)

ELAN Elanco
$35.23 /

+1.73 (+5.16%)

EADSY Airbus
$34.01 /

-0.02 (-0.06%)

DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

DISH Dish
$39.69 /

-0.335 (-0.84%)

DCRC Decarbonization Plus Acquisition III
$10.72 /

-1.31 (-10.89%)

CR Crane
$91.42 /

+0.61 (+0.67%)

CLSD Clearside Biomedical
$3.84 /

+0.8 (+26.32%)

CDAY Ceridian
$85.53 /

-3.65 (-4.09%)

BCOR Blucora
$18.37 /

+1.4 (+8.25%)

BBCP Concrete Pumping
$8.44 /

-0.1 (-1.17%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

ACRS Aclaris Therapeutics
$17.59 /

-0.14 (-0.79%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

06/15/21 Berenberg
Boeing price target raised to $245 from $215 at Berenberg
06/10/21 Jefferies
Boeing shares could move up 5% on China recertification, says Jefferies
06/09/21 Susquehanna
Boeing estimates lowered on light May deliveries, says Susquehanna
06/03/21 Morgan Stanley
Morgan Stanley says recovery tailwinds can offset new launch headwinds at Boeing
EADSY Airbus
$34.01 /

-0.02 (-0.06%)

06/15/21 Berenberg
Airbus price target raised to EUR 140 from EUR 110 at Berenberg
06/11/21 Credit Suisse
Airbus assumed with an Outperform at Credit Suisse
06/02/21 Barclays
Airbus price target raised to EUR 138 from EUR 113 at Barclays
06/02/21
Fly Intel: Top five analyst upgrades
NVAX Novavax
$189.20 /

-19 (-9.13%)

06/15/21 Cantor Fitzgerald
Novavax price target raised to $272 from $217 at Cantor Fitzgerald
06/07/21 B. Riley
Novavax risk/reward attractive into Covid vaccine data, says B. Riley
05/12/21
Fly Intel: Top five analyst downgrades
05/12/21 B. Riley
Novavax price target lowered to $286 from $365 at B. Riley
AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
CLSD Clearside Biomedical
$3.84 /

+0.8 (+26.32%)

06/15/21 Roth Capital
Clearside reported 'impressive' data in wet AMD, says Roth Capital
06/02/21 Roth Capital
Clearside success with Xipere can derisk pipeline, says Roth Capital
05/18/21 Roth Capital
Clearside Biomedical price target raised to $9 from $8 at Roth Capital
03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
DCRC Decarbonization Plus Acquisition III
$10.72 /

-1.31 (-10.89%)

WPC W.P. Carey
$77.50 /

-0.14 (-0.18%)

06/15/21
Fly Intel: Top five analyst upgrades
06/15/21 JPMorgan
JPMorgan upgrades W.P. Carey on swap out of Broadstone
06/15/21 JPMorgan
W.P. Carey upgraded to Overweight from Neutral at JPMorgan
05/03/21 Evercore ISI
W.P. Carey upgraded to Outperform at Evercore ISI on accelerating acquisitions
CR Crane
$91.42 /

+0.61 (+0.67%)

06/15/21 DA Davidson
Crane upgraded to Buy at DA Davidson following Engineered Materials divestment
06/15/21 DA Davidson
Crane upgraded to Buy from Neutral at DA Davidson
05/05/21 DA Davidson
Crane price target raised to $105 from $85 at DA Davidson
ACRS Aclaris Therapeutics
$17.59 /

-0.14 (-0.79%)

06/15/21
Fly Intel: Top five analyst initiations
06/15/21 Piper Sandler
Aclaris Therapeutics initiated with an Overweight at Piper Sandler
04/21/21 H.C. Wainwright
Aclaris Therapeutics initiated with a Buy at H.C. Wainwright
03/04/21 SVB Leerink
Aclaris Therapeutics price target raised to $26 from $21 at SVB Leerink
CDAY Ceridian
$85.53 /

-3.65 (-4.09%)

06/15/21
Fly Intel: Top five analyst downgrades
06/15/21 Needham
Ceridian downgraded to Hold from Buy at Needham
05/28/21 Jefferies
Ceridian price target lowered to $95 from $110 at Jefferies
05/06/21 Mizuho
Ceridian price target raised to $120 from $110 at Mizuho
FAST Fastenal
$51.70 /

-1.03 (-1.95%)

06/15/21 Morgan Stanley
Fastenal downgraded to Underweight from Equal Weight at Morgan Stanley
06/04/21 Raymond James
Fastenal's May ADS down 3.2% off challenging comparison, says Raymond James
05/03/21 Raymond James
Grainger price target raised to $460 from $400 at Raymond James
AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

06/15/21 JPMorgan
Amazon should surpass Walmart as largest retailer in 2022, says JPMorgan
06/14/21 Evercore ISI
Synchrony price target raised to $56 from $49 at Evercore ISI
06/08/21 Piper Sandler
New Amazon offering targets Hims & Hers and others, says Piper Sandler
06/08/21 UBS
Snowflake price target raised to $300 from $275 at UBS
DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

06/15/21 Credit Suisse
DraftKings selloff on short report overdone, says Credit Suisse
06/02/21 Morgan Stanley
DraftKings price target lowered to $58 from $63 at Morgan Stanley
05/24/21 Argus
DraftKings price target lowered to $60 from $78 at Argus
05/12/21
Fly Intel: Top five analyst upgrades
DISH Dish
$39.69 /

-0.335 (-0.84%)

06/09/21
Fly Intel: Top five analyst downgrades
06/09/21 JPMorgan
JPMorgan downgrades Dish to sell on wireless execution concerns
06/09/21 JPMorgan
Dish downgraded to Underweight from Neutral at JPMorgan
05/24/21 HSBC
Dish price target raised to $40 from $26 at HSBC
MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

06/15/21 Oppenheimer
Turtle Beach price target raised to $45 from $40 at Oppenheimer
06/07/21 Morgan Stanley
Microsoft valuation presents 'attractive entry point,' says Morgan Stanley
06/03/21 Tigress Financial
Microsoft shares going to $303 in 12 months, says Tigress Financial
06/01/21 KGI Securities
Microsoft initiated with an Outperform at KGI Securities
NFLX Netflix
$494.25 /

-5.35 (-1.07%)

06/01/21 KGI Securities
Netflix initiated with a Neutral at KGI Securities
05/27/21 Stifel
Stifel sees 'minimal impact' to Netflix from Amazon's MGM acquisition
05/27/21 Benchmark
Streaming field 'looking ever less unipolar around Netflix,' says Benchmark
05/26/21 Piper Sandler
Amazon deal to buy MGM Studios 'looks sensible,' says Piper Sandler
OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

06/11/21
Fly Intel: Top five analyst downgrades
06/11/21 H.C. Wainwright
Ocugen price target lowered to $10 from $12 at H.C. Wainwright
06/10/21 Roth Capital
Ocugen downgraded to Neutral from Buy at Roth Capital
06/10/21 Chardan
Ocugen price target lowered to $4.50 from $8 at Chardan
ELAN Elanco
$35.23 /

+1.73 (+5.16%)

06/15/21 Cleveland Research
Elanco upgraded to Neutral from Underperform at Cleveland Research
05/17/21 Citi
Elanco price target raised to $42 from $39 at Citi
05/11/21 Gabelli
Elanco upgraded to Buy from Hold at Gabelli
05/11/21 Barclays
Elanco upgraded to Equal Weight from Underweight at Barclays
FOA Finance of America
$8.83 /

+1.53 (+20.96%)

06/15/21 Raymond James
Finance of America upgraded to Strong Buy from Outperform at Raymond James
06/15/21 Raymond James
Finance of America upgraded to Strong Buy from Outperform at Raymond James
04/23/21 Raymond James
First of America initiated with an Outperform at Raymond James
SAGE Sage Therapeutics
$60.33 /

-12.55 (-17.22%)

06/15/21 Stifel
Sage, Biogen data support FDA approval in depression, says Stifel
06/15/21 Piper Sandler
Sage selloff on zuranolone data an overreaction, says Piper Sandler
05/05/21 Mizuho
Sage Therapeutics price target lowered to $77 from $81 at Mizuho
04/12/21 Oppenheimer
Sage Therapeutics data support 'enthusiasm' for SAGE-324 in ET, says Oppenheimer
VRM Vroom
$40.55 /

-4.58 (-10.15%)

05/13/21 Raymond James
Vroom price target raised to $53 from $47 at Raymond James
05/13/21 JMP Securities
Vroom price target raised to $55 from $48 at JMP Securities
05/13/21 Piper Sandler
Vroom price target lowered to $58 from $60 at Piper Sandler
04/13/21 Wedbush
Vroom added to Best List Ideas at Wedbush
SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

06/15/21 Citi
Spirit Airlines upgraded to Buy from Neutral at Citi
06/09/21 MKM Partners
MKM sees 'a lot to like' in Spirit Airlines' valuation
06/09/21 MKM Partners
Spirit Airlines initiated with a Buy at MKM Partners
QD Qudian
$2.25 /

-0.19 (-7.79%)

06/16/20 China Renaissance
China Renaissance ups LexinFintech to Buy, raises Fintech sector to Overweight
BCOR Blucora
$18.37 /

+1.4 (+8.25%)

04/01/21 JPMorgan
Blucora assumed with an Overweight at JPMorgan
02/17/21 Barrington
Blucora price target raised to $19 from $16 at Barrington
08/05/20 Barrington
Blucora price target lowered to $15 from $18 at Barrington
HLIO Helios Technologies
$72.61 /

+0.64 (+0.89%)

05/11/21 Baird
Helios Technologies price target raised to $89 from $84 at Baird
05/11/21 Baird
Helios Technologies updated guidance above previous range, says Baird
03/02/21 Baird
Helios Technologies price target raised to $82 from $72 at Baird
10/12/20 Baird
Helios Technologies upgraded to Outperform from Neutral at Baird
BBCP Concrete Pumping
$8.44 /

-0.1 (-1.17%)

06/15/21 Baird
Concrete Pumping price target raised to $11 from $10 at Baird
04/22/21 Baird
Concrete Pumping price target raised to $9 from $8 at Baird
01/13/21 B. Riley
Concrete Pumping price target lowered to $6 from $6.75 at B. Riley Securities
01/07/21 B. Riley
Concrete Pumping price target raised to $6.75 from $6.50 at B. Riley Securities
WPC W.P. Carey
$77.50 /

-0.14 (-0.18%)

VRM Vroom
$40.55 /

-4.58 (-10.15%)

SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

SAGE Sage Therapeutics
$60.33 /

-12.55 (-17.22%)

QD Qudian
$2.25 /

-0.19 (-7.79%)

OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

NVAX Novavax
$189.20 /

-19 (-9.13%)

NFLX Netflix
$494.25 /

-5.35 (-1.07%)

MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

HLIO Helios Technologies
$72.61 /

+0.64 (+0.89%)

FAST Fastenal
$51.70 /

-1.03 (-1.95%)

ELAN Elanco
$35.23 /

+1.73 (+5.16%)

EADSY Airbus
$34.01 /

-0.02 (-0.06%)

DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

DISH Dish
$39.69 /

-0.335 (-0.84%)

CR Crane
$91.42 /

+0.61 (+0.67%)

CLSD Clearside Biomedical
$3.84 /

+0.8 (+26.32%)

CDAY Ceridian
$85.53 /

-3.65 (-4.09%)

BCOR Blucora
$18.37 /

+1.4 (+8.25%)

BBCP Concrete Pumping
$8.44 /

-0.1 (-1.17%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

ACRS Aclaris Therapeutics
$17.59 /

-0.14 (-0.79%)

  • 10
    Jun
  • 08
    Jun
  • 20
    Jan
  • 07
    Dec
  • 01
    Dec
  • 19
    Nov
  • 07
    Oct
  • 11
    Sep
  • 26
    Aug
  • 18
    Jun
  • 19
    Jun
VRM Vroom
$40.55 /

-4.58 (-10.15%)

SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

NVAX Novavax
$189.20 /

-19 (-9.13%)

NFLX Netflix
$494.25 /

-5.35 (-1.07%)

MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

ELAN Elanco
$35.23 /

+1.73 (+5.16%)

EADSY Airbus
$34.01 /

-0.02 (-0.06%)

DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

DISH Dish
$39.69 /

-0.335 (-0.84%)

DCRC Decarbonization Plus Acquisition III
$10.72 /

-1.31 (-10.89%)

CR Crane
$91.42 /

+0.61 (+0.67%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

VRM Vroom
$40.55 /

-4.58 (-10.15%)

SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

NVAX Novavax
$189.20 /

-19 (-9.13%)

NFLX Netflix
$494.25 /

-5.35 (-1.07%)

MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

HLIO Helios Technologies
$72.61 /

+0.64 (+0.89%)

FAST Fastenal
$51.70 /

-1.03 (-1.95%)

ELAN Elanco
$35.23 /

+1.73 (+5.16%)

DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

DISH Dish
$39.69 /

-0.335 (-0.84%)

DCRC Decarbonization Plus Acquisition III
$10.72 /

-1.31 (-10.89%)

CR Crane
$91.42 /

+0.61 (+0.67%)

CDAY Ceridian
$85.53 /

-3.65 (-4.09%)

BBCP Concrete Pumping
$8.44 /

-0.1 (-1.17%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

ACRS Aclaris Therapeutics
$17.59 /

-0.14 (-0.79%)

VRM Vroom
$40.55 /

-4.58 (-10.15%)

SAVE Spirit Airlines
$33.83 /

-0.125 (-0.37%)

QD Qudian
$2.25 /

-0.19 (-7.79%)

OCGN Ocugen
$6.59 /

+0.44 (+7.15%)

NVAX Novavax
$189.20 /

-19 (-9.13%)

NFLX Netflix
$494.25 /

-5.35 (-1.07%)

MSFT Microsoft
$259.24 /

-0.71 (-0.27%)

FOA Finance of America
$8.83 /

+1.53 (+20.96%)

DKNG DraftKings
$48.28 /

-2.34 (-4.62%)

DISH Dish
$39.69 /

-0.335 (-0.84%)

BA Boeing
$245.71 /

+0.64 (+0.26%)

AZN AstraZeneca
$58.62 /

-0.13 (-0.22%)

AMZN Amazon.com
$3,371.43 /

-11.19 (-0.33%)

Recommendations
Clearside reported 'impressive' data in wet AMD, says Roth Capital » 11:48
06/15/21
06/15
11:48
06/15/21
11:48
CLSD

Clearside Biomedical

$3.90 /

+0.86 (+28.29%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah reiterates a Buy rating on Clearside Biomedical with a $9 price target after the company announced "impressive" early safety and efficacy data from Cohort 1 of its Phase 1/2a study of CLS-AX in pretreated wet age-related macular degeneration patients. CLS-AX was safe and well-tolerated with no inflammation, allowing for enrollment into Cohort 2, Jallah tells investors in a research note. Even "more impressive" was the early efficacy data showing that a single-dose of CLX-AX led to best corrected visual acuity improvements, beyond that achieved with "gold-standard" Eylea, which is a "game changer," says the analyst.

ShowHide Related Items >><<
CLSD Clearside Biomedical
$3.90 /

+0.86 (+28.29%)

CLSD Clearside Biomedical
$3.90 /

+0.86 (+28.29%)

06/02/21 Roth Capital
Clearside success with Xipere can derisk pipeline, says Roth Capital
05/18/21 Roth Capital
Clearside Biomedical price target raised to $9 from $8 at Roth Capital
03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
12/03/20 Roth Capital
Clearside platform validated by Janssen deal, says Roth Capital
CLSD Clearside Biomedical
$3.90 /

+0.86 (+28.29%)

CLSD Clearside Biomedical
$3.90 /

+0.86 (+28.29%)

On The Fly
Fly Intel: Pre-market Movers » 08:54
06/15/21
06/15
08:54
06/15/21
08:54
BCOR

Blucora

$16.95 /

-0.01 (-0.06%)

, CLSD

Clearside Biomedical

$3.04 /

+0.02 (+0.66%)

, SAVE

Spirit Airlines

$33.96 /

-0.385 (-1.12%)

, NVAX

Novavax

$208.27 /

-1.33 (-0.63%)

, QD

Qudian

$2.44 /

+0.34 (+16.19%)

, DCRC

Decarbonization Plus Acquisition III

$12.03 /

-0.36 (-2.91%)

, DSS

Document Security

$2.78 /

-0.175 (-5.92%)

, SAGE

Sage Therapeutics

$72.85 /

-6.31 (-7.97%)

, PING

Ping Identity

$24.57 /

-0.15 (-0.61%)

, UFAB

Unique Fabricating

$3.27 /

-0.03 (-0.91%)

Check out this morning's…

ShowHide Related Items >><<
UFAB Unique Fabricating
$3.27 /

-0.03 (-0.91%)

SAVE Spirit Airlines
$33.96 /

-0.385 (-1.12%)

SAGE Sage Therapeutics
$72.85 /

-6.31 (-7.97%)

QD Qudian
$2.44 /

+0.34 (+16.19%)

PING Ping Identity
$24.57 /

-0.15 (-0.61%)

NVAX Novavax
$208.27 /

-1.33 (-0.63%)

DSS Document Security
$2.78 /

-0.175 (-5.92%)

DCRC Decarbonization Plus Acquisition III
$12.03 /

-0.36 (-2.91%)

CLSD Clearside Biomedical
$3.04 /

+0.02 (+0.66%)

BCOR Blucora
$16.95 /

-0.01 (-0.06%)

BCOR Blucora
$16.95 /

-0.01 (-0.06%)

04/01/21 JPMorgan
Blucora assumed with an Overweight at JPMorgan
02/17/21 Barrington
Blucora price target raised to $19 from $16 at Barrington
08/05/20 Barrington
Blucora price target lowered to $15 from $18 at Barrington
CLSD Clearside Biomedical
$3.04 /

+0.02 (+0.66%)

06/02/21 Roth Capital
Clearside success with Xipere can derisk pipeline, says Roth Capital
05/18/21 Roth Capital
Clearside Biomedical price target raised to $9 from $8 at Roth Capital
03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
12/03/20 Roth Capital
Clearside platform validated by Janssen deal, says Roth Capital
SAVE Spirit Airlines
$33.96 /

-0.385 (-1.12%)

06/15/21 Citi
Spirit Airlines upgraded to Buy from Neutral at Citi
06/09/21 MKM Partners
MKM sees 'a lot to like' in Spirit Airlines' valuation
06/09/21 MKM Partners
Spirit Airlines initiated with a Buy at MKM Partners
05/14/21 Wolfe Research
Spirit Airlines upgraded to Peer Perform from Underperform at Wolfe Research
NVAX Novavax
$208.27 /

-1.33 (-0.63%)

06/15/21 Cantor Fitzgerald
Novavax price target raised to $272 from $217 at Cantor Fitzgerald
06/07/21 B. Riley
Novavax risk/reward attractive into Covid vaccine data, says B. Riley
05/12/21
Fly Intel: Top five analyst downgrades
05/12/21 B. Riley
Novavax price target lowered to $286 from $365 at B. Riley
QD Qudian
$2.44 /

+0.34 (+16.19%)

06/16/20 China Renaissance
China Renaissance ups LexinFintech to Buy, raises Fintech sector to Overweight
DCRC Decarbonization Plus Acquisition III
$12.03 /

-0.36 (-2.91%)

DSS Document Security
$2.78 /

-0.175 (-5.92%)

06/24/20 Aegis
Document Security assumed with a Buy at Aegis
SAGE Sage Therapeutics
$72.85 /

-6.31 (-7.97%)

06/15/21 Piper Sandler
Sage selloff on zuranolone data an overreaction, says Piper Sandler
05/05/21 Mizuho
Sage Therapeutics price target lowered to $77 from $81 at Mizuho
04/12/21 Oppenheimer
Sage Therapeutics data support 'enthusiasm' for SAGE-324 in ET, says Oppenheimer
04/12/21 Piper Sandler
Sage Therapeutics essential tremor data 'a win,' says Piper Sandler
PING Ping Identity
$24.57 /

-0.15 (-0.61%)

06/11/21 Needham
Needham starts Ping Identity at Hold, sees upside potential 'baked in'
06/11/21 Needham
Ping Identity initiated with a Hold at Needham
05/24/21 Stifel
Ping Identity resumed with a Hold at Stifel
04/16/21 Barclays
Ping Identity price target lowered to $27 from $33 at Barclays
UFAB Unique Fabricating
$3.27 /

-0.03 (-0.91%)

SAVE Spirit Airlines
$33.96 /

-0.385 (-1.12%)

SAGE Sage Therapeutics
$72.85 /

-6.31 (-7.97%)

QD Qudian
$2.44 /

+0.34 (+16.19%)

PING Ping Identity
$24.57 /

-0.15 (-0.61%)

NVAX Novavax
$208.27 /

-1.33 (-0.63%)

DSS Document Security
$2.78 /

-0.175 (-5.92%)

CLSD Clearside Biomedical
$3.04 /

+0.02 (+0.66%)

BCOR Blucora
$16.95 /

-0.01 (-0.06%)

  • 15
    Jun
  • 15
    Jun
  • 10
    Oct
  • 05
    Feb
  • 20
    Jan
  • 15
    Dec
  • 28
    Jul
  • 09
    Jul
  • 02
    Jul
SAVE Spirit Airlines
$33.96 /

-0.385 (-1.12%)

NVAX Novavax
$208.27 /

-1.33 (-0.63%)

DCRC Decarbonization Plus Acquisition III
$12.03 /

-0.36 (-2.91%)

UFAB Unique Fabricating
$3.27 /

-0.03 (-0.91%)

SAVE Spirit Airlines
$33.96 /

-0.385 (-1.12%)

PING Ping Identity
$24.57 /

-0.15 (-0.61%)

NVAX Novavax
$208.27 /

-1.33 (-0.63%)

DCRC Decarbonization Plus Acquisition III
$12.03 /

-0.36 (-2.91%)

SAVE Spirit Airlines
$33.96 /

-0.385 (-1.12%)

QD Qudian
$2.44 /

+0.34 (+16.19%)

NVAX Novavax
$208.27 /

-1.33 (-0.63%)

DSS Document Security
$2.78 /

-0.175 (-5.92%)

Hot Stocks
Clearside report 'positive' safety results from OASIS Phase 1/2a trial of CLS-AX » 07:25
06/15/21
06/15
07:25
06/15/21
07:25
CLSD

Clearside Biomedical

$3.04 /

+0.02 (+0.66%)

Clearside Biomedical…

Clearside Biomedical announced positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX administered by suprachoroidal injection via Clearside's SCS Microinjector in six patients with neovascular age-related macular degeneration. The primary endpoints were achieved in Cohort 1, as the initial lowest planned dose of 0.03 mg CLS-AX was well tolerated with no serious adverse events and no drug related treatment emergent adverse events observed throughout the study period. There were no signs of inflammation, no vasculitis, no intraocular pressure safety signals, no dispersion of drug into the vitreous, or any other drug related adverse events observed in any of the patients. The OASIS Safety Monitoring Committee has reviewed the data and the trial will advance to Cohort 2. Clearside expects to begin Cohort 2 patient screening for a dose of 0.1 mg CLS-AX in June 2021 with completion of this four month study period expected by the end of the year. "We are very encouraged by the Cohort 1 results of the OASIS trial and we are immediately beginning Cohort 2 enrollment as planned," said Thomas A. Ciulla, M.D., MBA, Chief Medical Officer and Chief Development Officer. "The initial data from Cohort 1 clearly achieved our safety and tolerability endpoints. While still early and recognizing there are a limited number of patients, we believe the Cohort 1 data supports our hypothesis that the combination of targeted and compartmentalized suprachoroidal delivery and the potent pan-VEGF attributes of axitinib may facilitate an effective treatment option for patients suffering from wet AMD."

ShowHide Related Items >><<
CLSD Clearside Biomedical
$3.04 /

+0.02 (+0.66%)

CLSD Clearside Biomedical
$3.04 /

+0.02 (+0.66%)

06/02/21 Roth Capital
Clearside success with Xipere can derisk pipeline, says Roth Capital
05/18/21 Roth Capital
Clearside Biomedical price target raised to $9 from $8 at Roth Capital
03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
12/03/20 Roth Capital
Clearside platform validated by Janssen deal, says Roth Capital
CLSD Clearside Biomedical
$3.04 /

+0.02 (+0.66%)

Recommendations
Clearside success with Xipere can derisk pipeline, says Roth Capital » 13:38
06/02/21
06/02
13:38
06/02/21
13:38
CLSD

Clearside Biomedical

$2.79 /

+0.13 (+4.89%)

, BHC

Bausch Health

$31.95 /

-0.085 (-0.27%)

After Clearside…

After Clearside Biomedical (CLSD) and partner Bausch Health Companies (BHC) announced that the FDA has accepted the resubmitted New Drug Application for Xipere, Roth Capital analyst Zegbeh Jallah noted that progress had been slowed by manufacturing issues that resulted in a CRL. However, based on the NDA acceptance, the FDA's concerns have now been addressed, said Jallah, who is "clearly very bullish" on approval in October and a commercial launch in 2022. The analyst, who thinks approval of Xipere should derisk Clearside's SCS Microinjector and give Clearside some non-dilutive capital to advance its pipeline, keeps a Buy rating on the shares and identifies the stock as a 2021 top pick.

ShowHide Related Items >><<
CLSD Clearside Biomedical
$2.79 /

+0.13 (+4.89%)

BHC Bausch Health
$31.95 /

-0.085 (-0.27%)

CLSD Clearside Biomedical
$2.79 /

+0.13 (+4.89%)

05/18/21 Roth Capital
Clearside Biomedical price target raised to $9 from $8 at Roth Capital
03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
12/03/20 Roth Capital
Clearside platform validated by Janssen deal, says Roth Capital
08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
BHC Bausch Health
$31.95 /

-0.085 (-0.27%)

03/24/21
Fly Intel: Top five analyst downgrades
03/24/21 BofA
BofA downgrades Bausch Health to Underperform, sees stock 'priced to perfection'
03/24/21 BofA
Bausch Health downgraded to Underperform from Neutral at BofA
03/16/21 H.C. Wainwright
Bausch Health price target raised to $55 from $50 at H.C. Wainwright
CLSD Clearside Biomedical
$2.79 /

+0.13 (+4.89%)

BHC Bausch Health
$31.95 /

-0.085 (-0.27%)

BHC Bausch Health
$31.95 /

-0.085 (-0.27%)

BHC Bausch Health
$31.95 /

-0.085 (-0.27%)

BHC Bausch Health
$31.95 /

-0.085 (-0.27%)

Hot Stocks
Bausch Health, Clearside announce FDA filing acceptance for XIPERE » 07:03
06/02/21
06/02
07:03
06/02/21
07:03
BHC

Bausch Health

$32.04 /

-0.135 (-0.42%)

, CLSD

Clearside Biomedical

$2.66 /

+0.09 (+3.50%)

Bausch Health Companies…

Bausch Health Companies (BHC) along with Clearside Biomedical (CLSD) announced that the U.S. Food and Drug Administration has accepted the resubmitted New Drug Application for XIPERE. FDA determined that the filing is a Class 2 resubmission and therefore assigned a Prescription Drug User Fee Act action date of October 30, 2021. XIPERE is an investigational therapy with a proposed indication of treatment of macular edema associated with uveitis.

ShowHide Related Items >><<
CLSD Clearside Biomedical
$2.66 /

+0.09 (+3.50%)

BHC Bausch Health
$32.04 /

-0.135 (-0.42%)

BHC Bausch Health
$32.04 /

-0.135 (-0.42%)

03/24/21
Fly Intel: Top five analyst downgrades
03/24/21 BofA
BofA downgrades Bausch Health to Underperform, sees stock 'priced to perfection'
03/24/21 BofA
Bausch Health downgraded to Underperform from Neutral at BofA
03/16/21 H.C. Wainwright
Bausch Health price target raised to $55 from $50 at H.C. Wainwright
CLSD Clearside Biomedical
$2.66 /

+0.09 (+3.50%)

05/18/21 Roth Capital
Clearside Biomedical price target raised to $9 from $8 at Roth Capital
03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
12/03/20 Roth Capital
Clearside platform validated by Janssen deal, says Roth Capital
08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
CLSD Clearside Biomedical
$2.66 /

+0.09 (+3.50%)

BHC Bausch Health
$32.04 /

-0.135 (-0.42%)

BHC Bausch Health
$32.04 /

-0.135 (-0.42%)

BHC Bausch Health
$32.04 /

-0.135 (-0.42%)

BHC Bausch Health
$32.04 /

-0.135 (-0.42%)

Over a month ago
Recommendations
Clearside Biomedical price target raised to $9 from $8 at Roth Capital » 10:31
05/18/21
05/18
10:31
05/18/21
10:31
CLSD

Clearside Biomedical

$2.37 /

-0.03 (-1.25%)

Roth Capital analyst…

Roth Capital analyst Zegbeh Jallah raised the firm's price target on Clearside Biomedical to $9 from $8 and keeps a Buy rating on the shares following the company's Q1 update. The analyst expects approval of Xipere by the end of 2021. The new drug application has been filed for Xipere, Clearside's suprachoroidally-delivered, proprietary formulation of triamcinolone for uveitis, which should trigger milestones from Bausch and Arctic Vision, Jallah tells investors in a research note. The analyst expects management to receive a response from the FDA around June 4 that should confirm the timing of the action date. Given expectations for a six-month review process, this could set the stage for a PDUFA by the end of 2021, says Jallah.

ShowHide Related Items >><<
CLSD Clearside Biomedical
$2.37 /

-0.03 (-1.25%)

CLSD Clearside Biomedical
$2.37 /

-0.03 (-1.25%)

03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
12/03/20 Roth Capital
Clearside platform validated by Janssen deal, says Roth Capital
08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/19/20 Roth Capital
Clearside Biomedical abstracts highlight strength, says Roth Capital
CLSD Clearside Biomedical
$2.37 /

-0.03 (-1.25%)

Earnings
Clearside Biomedical reports Q1 EPS (10c), consensus (13c) » 16:23
05/17/21
05/17
16:23
05/17/21
16:23
CLSD

Clearside Biomedical

$2.40 /

-0.01 (-0.41%)

Reports Q1 revenue…

Reports Q1 revenue $34,000, consensus $2.12M. "We have made meaningful, value-creating progress over the past several months," said George Lasezkay, Clearside's president and CEO. "In late April, we resubmitted our New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for XIPERETM for the treatment of macular edema associated with uveitis. This milestone is important as XIPERE would be Clearside's first commercial product if approved by the FDA, and it would also be the first approved drug to be delivered into the suprachoroidal space (SCS(R)). Our innovative platform represents a potential breakthrough for delivering drugs to the back of the eye using a reliable, non-surgical, office-based method."

ShowHide Related Items >><<
CLSD Clearside Biomedical
$2.40 /

-0.01 (-0.41%)

CLSD Clearside Biomedical
$2.40 /

-0.01 (-0.41%)

03/02/21 Roth Capital
Clearside enrollment speed 'encouraging,' says Roth Capital
12/03/20 Roth Capital
Clearside platform validated by Janssen deal, says Roth Capital
08/06/20 Roth Capital
Investors should buy 'highly undervalued' Clearside, says Roth Capital
06/19/20 Roth Capital
Clearside Biomedical abstracts highlight strength, says Roth Capital

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.